Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GILD Stock Forecast 2026-2027
$129.16
Current Price
$160.36B
Market Cap
Buy 24
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to GILD Price Targets
+39.4%
To High Target of $180.00
+23.9%
To Median Target of $160.00
-5.5%
To Low Target of $122.00
GILD Price Momentum
-3.9%
1 Week Change
-3.7%
1 Month Change
+14.8%
1 Year Change
+5.2%
Year-to-Date Change
-17.9%
From 52W High of $157.29
+23.6%
From 52W Low of $104.46
📊 TOP ANALYST CALLS
Did GILD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Gilead is one of their latest high-conviction picks.
Latest GILD Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, GILD has a bullish consensus with a median price target of $160.00 (ranging from $122.00 to $180.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $129.16, the median forecast implies a 23.9% upside. This outlook is supported by 24 Buy, 7 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GILD Analyst Ratings
24
Buy
7
Hold
0
Sell
GILD Price Target Range
Low
$122.00
Average
$160.00
High
$180.00
Current: $129.16
Latest GILD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GILD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 20, 2026 | Maxim Group | Michael Okunewitch | Buy | Upgrade | $165.00 |
| May 8, 2026 | Truist Securities | Buy | Reiterates | $N/A | |
| May 8, 2026 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Apr 13, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Apr 10, 2026 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Mar 10, 2026 | Jefferies | Buy | Initiates | $N/A | |
| Feb 23, 2026 | Needham | Buy | Reiterates | $N/A | |
| Feb 20, 2026 | Barclays | Equal-Weight | Initiates | $N/A | |
| Feb 11, 2026 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Feb 11, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Feb 11, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Feb 11, 2026 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Feb 11, 2026 | Scotiabank | Sector Outperform | Maintains | $N/A | |
| Feb 11, 2026 | Needham | Buy | Maintains | $N/A | |
| Jan 27, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Jan 27, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Jan 26, 2026 | UBS | Buy | Maintains | $N/A | |
| Jan 13, 2026 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Jan 7, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Jan 7, 2026 | UBS | Michael Yee | Buy | Assumes | $145.00 |
Gilead Sciences Inc. (GILD) Competitors
The following stocks are similar to Gilead based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Gilead Sciences Inc. (GILD) Financial Data
Gilead Sciences Inc. has a market capitalization of $160.36B with a P/E ratio of 17.6x. The company generates $29.74B in trailing twelve-month revenue with a 31.0% profit margin.
Revenue growth is +4.4% quarter-over-quarter, while maintaining an operating margin of +39.3% and return on equity of +43.4%.
Valuation Metrics
Market Cap
$160.36B
Enterprise Value
$172.66B
P/E Ratio
17.6x
PEG Ratio
0.3x
Price/Sales
5.4x
Growth & Margins
Revenue Growth (YoY)
+4.4%
Gross Margin
+79.2%
Operating Margin
+39.3%
Net Margin
+31.0%
EPS Growth
+53.7%
Financial Health
Cash/Price Ratio
+6.1%
Current Ratio
2.0x
Debt/Equity
94.6x
ROE
+43.4%
ROA
+13.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Gilead Sciences Inc. (GILD) Business Model
About Gilead Sciences Inc.
What They Do
Biopharmaceutical company focused on innovative medicines.
Business Model
The company discovers, develops, and commercializes medicines for unmet medical needs in areas such as infectious diseases and oncology. Gilead generates revenue primarily through the sale of its extensive portfolio of treatments, including leading products for HIV and viral hepatitis, as well as therapies for cancer and COVID-19.
Additional Information
Founded in 1987 and headquartered in Foster City, California, Gilead Sciences has a strong presence in the U.S., Europe, and international markets. Its innovative product offerings include the world's first twice-yearly HIV prevention therapy and advanced treatments for various life-threatening conditions, positioning the company as a key player in the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
17,000
CEO
Mr. Daniel P. O'Day
Country
United States
IPO Year
1992
Website
www.gilead.comGilead Sciences Inc. (GILD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
Jun 04, 2026
By Zacks Equity Research
Analyst Blog
GILD Reports Positive Results From Late-Stage Liver Disease Study
Gilead reports positive phase III IDEAL results as Livdelzi boosts ALP normalization in PBC patients, supporting regulatory discussions.
Jun 03, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
2 days ago
Quick Summary
Gilead praises South Africa and the Global Fund for enhancing access to lenacapavir, a long-acting HIV prevention drug, marking a significant advancement in HIV prevention efforts.
Why It Matters
Gilead's expansion of lenacapavir in South Africa signals potential revenue growth and increased market share in the HIV treatment sector, positively impacting investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Assembly Biosciences (ASMB) is awaiting a development plan from Gilead for its herpes simplex virus programs and is advancing ABI-6250 for multiple liver disease indications.
Why It Matters
Assembly Biosciences' progress with ABI-6250 and its partnership with Gilead could significantly impact its valuation and market potential, influencing investor sentiment and stock performance.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Companies are partnering to develop gamgertamig, a potential first-in-class T cell engager targeting autoimmune diseases.
Why It Matters
Collaboration on a novel T cell engager for autoimmune diseases could lead to significant breakthroughs, impacting market potential and stock performance of involved companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Gilead Sciences and Lakefront Biotherapeutics have successfully acquired Ouro Medicines to enhance T cell engager therapies for autoimmune diseases, adding OM336 to Gilead's inflammation portfolio.
Why It Matters
Gilead's acquisition of Ouro Medicines enhances its pipeline in T cell engager therapies, potentially boosting revenue and competitive positioning in the autoimmune disease market.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Gilead Sciences, Inc. announced results from the Phase 3 IDEAL study focused on primary biliary cholangitis (PBC) on Tuesday.
Why It Matters
Gilead's Phase 3 IDEAL study results could impact its stock performance and market position in treating PBC, influencing investor sentiment and future revenue potential.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Gilead's phase III IDEAL trial shows Livdelzi effectively normalizes ALP levels in PBC patients, aiding in regulatory discussions for the drug's approval.
Why It Matters
Positive phase III results for Gilead's Livdelzi indicate potential for market approval, enhancing growth prospects and investor confidence in the company's pipeline and future earnings.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About GILD Stock
What is Gilead Sciences Inc.'s (GILD) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Gilead Sciences Inc. (GILD) has a median price target of $160.00. The highest price target is $180.00 and the lowest is $122.00.
Is GILD stock a good investment in 2026?
According to current analyst ratings, GILD has 24 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $129.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GILD stock?
Wall Street analysts predict GILD stock could reach $160.00 in the next 12 months. This represents a 23.9% increase from the current price of $129.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Gilead Sciences Inc.'s business model?
The company discovers, develops, and commercializes medicines for unmet medical needs in areas such as infectious diseases and oncology. Gilead generates revenue primarily through the sale of its extensive portfolio of treatments, including leading products for HIV and viral hepatitis, as well as therapies for cancer and COVID-19.
What is the highest forecasted price for GILD Gilead Sciences Inc.?
The highest price target for GILD is $180.00 from at , which represents a 39.4% increase from the current price of $129.16.
What is the lowest forecasted price for GILD Gilead Sciences Inc.?
The lowest price target for GILD is $122.00 from at , which represents a -5.5% decrease from the current price of $129.16.
What is the overall GILD consensus from analysts for Gilead Sciences Inc.?
The overall analyst consensus for GILD is bullish. Out of 8 Wall Street analysts, 24 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $160.00.
How accurate are GILD stock price projections?
Stock price projections, including those for Gilead Sciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 3:01 PM UTC